Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term Antineoplastic Agents. Found 201 abstracts

no pagination
Feitelson MA, Arzumanyan A, Kulathinal RJ, Blain SW, Holcombe RF, Mahajna J, Marino M, Martinez-Chantar ML, Nawroth R, Sanchez-Garcia I, Sharma D, Saxena NK, Singh N, Vlachostergios PJ, Guo S, Honoki K, Fujii H, Georgakilas AG, Bilsland A, Amedei A, Niccolai E, Amin A, Ashraf SS, Boosani CS, Guha G, Ciriolo MR, Aquilano K, Chen S, Mohammed SI, Azmi AS, Bhakta D, Halicka D, Keith WN, Nowsheen S. Sustained proliferation in cancer: Mechanisms and novel therapeutic targets. Semin Cancer Biol. 2015 Dec;35 Suppl:S25-54.   PMCID: PMC4898971
Galloway TJ, Wirth LJ, Colevas AD, Gilbert J, Bauman JE, Saba NF, Raben D, Mehra R, Ma AW, Atoyan R, Wang J, Burtness B, Jimeno A. A Phase I Study of CUDC-101, a Multitarget Inhibitor of HDACs, EGFR, and HER2, in Combination with Chemoradiation in Patients with Head and Neck Squamous Cell Carcinoma. Clin Cancer Res. 2015 Apr;21(7):1566-73.
Higuchi T, Flies DB, Marjon NA, Mantia-Smaldone G, Ronner L, Gimotty PA, Adams S. CTLA-4 blockade synergizes therapeutically with PARP-inhibition in BRCA1-deficient ovarian cancer. Cancer Immunol Res. 2015 Jul 02;3(11):1257-68.   PMCID: 4984269
Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G, Plimack ER, Castellano D, Choueiri TK, Gurney H, Donskov F, Bono P, Wagstaff J, Gauler TC, Ueda T, Tomita Y, Schutz FA, Kollmannsberger C, Larkin J, Ravaud A, Simon JS, Xu LA, Waxman IM, Sharma P, CheckMate I. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. The New England journal of medicine. 2015 Nov 05;373(19):1803-13.
Motzer RJ, Rini BI, McDermott DF, Redman BG, Kuzel TM, Harrison MR, Vaishampayan UN, Drabkin HA, George S, Logan TF, Margolin KA, Plimack ER, Lambert AM, Waxman IM, Hammers HJ. Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial. J Clin Oncol. 2015 May;33(13):1430-7.   PMCID: PMC4806782
Najjar M, Suebsuwong C, Ray S, Thapa R, Maki J, Nogusa S, Shah S, Saleh D, Gough P, Bertin J, Yuan J, Balachandran S, Cuny G, Degterev A. Structure guided design of potent and selective ponatinib-based hybrid inhibitors for RIPK1. Cell Reports. 2015 Mar 24;10(11):1850-60.   PMCID: 4494889
Peethambaram PP, Hartmann LC, Jonker DJ, de Jonge M, Plummer ER, Martin L, Konner J, Marshall J, Goss GD, Teslenko V, Clemens PL, Cohen LJ, Ahlers CM, Alland L. A phase I pharmacokinetic and safety analysis of epothilone folate (BMS-753493), a folate receptor targeted chemotherapeutic agent in humans with advanced solid tumors. Invest New Drugs. 2015 Apr;33(2):321-31.
Plimack ER, Dunbrack RL, Brennan TA, Andrake MD, Zhou Y, Serebriiskii IG, Slifker M, Alpaugh K, Dulaimi E, Palma N, Hoffman-Censits J, Bilusic M, Wong YN, Kutikov A, Viterbo R, Greenberg RE, Chen DY, Lallas CD, Trabulsi EJ, Yelensky R, McConkey DJ, Miller VA, Golemis EA, Ross EA. Defects in DNA Repair Genes Predict Response to Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder Cancer. Eur Urol. 2015 Dec;68(6):959-67.   PMCID: PMC4764095
Pogash TJ, El-Bayoumy K, Amin S, Gowda K, de Cicco RL, Barton M, Su Y, Russo IH, Himmelberger JA, Slifker M, Manni A, Russo J. Oxidized derivative of docosahexaenoic acid preferentially inhibit cell proliferation in triple negative over luminal breast cancer cells. In Vitro Cell Dev Biol Anim. 2015 Feb;51(2):121-7.   PMCID: 4948656
Sasano T, Mabuchi S, Kuroda H, Kawano M, Matsumoto Y, Takahashi R, Hisamatsu T, Sawada K, Hashimoto K, Isobe A, Testa JR, Kimura T. Preclinical efficacy for AKT targeting in clear cell carcinoma of the ovary. Molecular Cancer Research. 2015 Apr;13(4):795-806.   PMCID: PMC4398602
Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M, Wong YN, Hahn N, Kohli M, Cooney MM, Dreicer R, Vogelzang NJ, Picus J, Shevrin D, Hussain M, Garcia JA, DiPaola RS. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. The New England journal of medicine. 2015 Aug 20;373(8):737-46.   PMCID: 4562797
Talekar MK, Allen JE, Dicker DT, El-Deiry WS. ONC201 induces cell death in pediatric non-Hodgkin's lymphoma cells. Cell cycle (Georgetown, Tex). 2015 Aug;14(15):2422-8.   PMCID: PMC4614396
Wong SJ, Moughan J, Meropol NJ, Anne PR, Kachnic LA, Rashid A, Watson JC, Mitchell EP, Pollock J, Lee RJ, Haddock M, Erickson BA, Willett CG. Efficacy Endpoints of Radiation Therapy Group Protocol 0247: A Randomized, Phase 2 Study of Neoadjuvant Radiation Therapy Plus Concurrent Capecitabine and Irinotecan or Capecitabine and Oxaliplatin for Patients With Locally Advanced Rectal Cancer. International Journal of Radiation Oncology Biology Physics. 2015 Jan;91(1):116-23.   PMCID: 4385459
Wuthrick EJ, Zhang Q, Machtay M, Rosenthal DI, Nguyen-Tan PF, Fortin A, Silverman CL, Raben A, Kim HE, Horwitz EM, Read NE, Harris J, Wu Q, Le QT, Gillison ML. Institutional clinical trial accrual volume and survival of patients with head and neck cancer. J Clin Oncol. 2015 Jan 10;33(2):156-64.   PMCID: PMC4279235
Zhang I, Zaorsky NG, Palmer JD, Mehra R, Lu B. Targeting brain metastases in ALK-rearranged non-small-cell lung cancer. Lancet Oncol. 2015 Oct;16(13):e510-21.
Zibelman M, Barth P, Handorf E, Smaldone MC, Kutikov A, Uzzo RG, Bilusic M, Plimack ER, Wong YN, Geynisman DM. A review of interventional clinical trials in renal cell carcinoma: a status report from the ClinicalTrials.gov WebSite. Clin Genitourin Cancer. 2015 Apr;13(2):142-9.
Barta SK, Xue X, Wang D, Lee JY, Kaplan LD, Ribera JM, Oriol A, Spina M, Tirelli U, Boue F, Wilson WH, Wyen C, Dunleavy K, Noy A, Sparano JA. A new prognostic score for AIDS-related lymphomas in the rituximab-era. Haematologica. 2014 Nov;99(11):1731-7.   PMCID: 4222464
Goldsack JC, Reilly C, Bush C, McElligott S, Bristol MN, Motanya UN, Field R, Vozniak JM, Wong YN, Schwartz JS, Domchek S. Impact of shortages of injectable oncology drugs on patient care. Am J Health Syst Pharm. 2014 Apr;71(7):571-8.
Haluska P, Menefee M, Plimack ER, Rosenberg J, Northfelt D, LaVallee T, Shi L, Yu XQ, Burke P, Huang J, Viner J, McDevitt J, LoRusso P. Phase I dose-escalation study of MEDI-573, a bispecific, antiligand monoclonal antibody against IGFI and IGFII, in patients with advanced solid tumors. Clin Cancer Res. 2014 Sep 15;20(18):4747-57.   PMCID: 4377301
Infante JR, Dees EC, Olszanski AJ, Dhuria SV, Sen S, Cameron S, Cohen RB. Phase I Dose-Escalation Study of LCL161, an Oral Inhibitor of Apoptosis Proteins Inhibitor, in Patients With Advanced Solid Tumors. J Clin Oncol. 2014 Oct;32(28):3103-10.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term Antineoplastic Agents

Antineoplastic Agents Female therapeutic use drug therapy Middle Aged pathology Male Aged Adult mortality administration & dosage adverse effects metabolism drug effects therapy antagonists & inhibitors Drug Dose-Response Relationship Drug Administration Schedule Neoplasms Treatment Outcome 80 and over Aged Cisplatin Monoclonal Antibodies pharmacology Chemoradiotherapy genetics analogs & derivatives Tumor Cell Line methods Maximum Tolerated Dose Renal Cell Carcinoma Kidney Neoplasms pharmacokinetics Kaplan-Meier Estimate Survival Analysis Signal Transduction Head and Neck Neoplasms Prognosis chemically induced Inbred C57BL Mice Squamous Cell Carcinoma Neoadjuvant Therapy Disease-Free Survival Ovarian Neoplasms Protein Kinase Inhibitors immunology Cell Proliferation Prospective Studies Mice Molecular Targeted Therapy biosynthesis Immunotherapy Tumor Biomarkers Clinical Trials as Topic secondary Neoplasm Drug Resistance Tumor Necrosis Factor Receptors antagonists & Lung Neoplasms Folic Acid Clear Cell Adenocarcinoma Neoplastic Stem Cells Internet Tablets Molecular Docking Simulation Rb1 Urothelial carcinoma epidemiology Trail Targeted therapy Unsaturated Fatty Acids blood Camptothecin Disease Progression Area Under Curve TNF-related apoptosis-inducing ligand TRAIL Leucovorin Breast Neoplasms Hydroxamic Acids Onc201 Pharmaceutical Solutions DNA Repair secretion lymphoma Dose Fractionation CTLA-4 Antigen Non-Small-Cell Lung Carcinoma Intravenous Administration Finland non-Hodgkin's lymphoma NHL Canada Capecitabine Half-Life Salvage Therapy Proportional Hazards Models Taxoids Ubiquitin-Protein Ligases T-Lymphocyte Subsets Nhl Pyridazines deficiency Prostatic Neoplasms Young Adult Follow-Up Studies Viral Load Imidazoles Preclinical Drug Evaluation Biological Availability Jurkat Cells Amino Acid Sequence Radiotherapy Dosage ErbB-2 Receptor Rectal Neoplasms Brain Neoplasms AIDS-Related Lymphoma Epidermal Growth Factor Receptor TOR Serine-Threonine Kinases Oral Administration Italy Radiotherapy Triple Negative Breast Neoplasms HEK293 Cells Urinary Bladder Neoplasms Blood-Brain Barrier Cell Survival Atm Combination Drug Therapy Cell Cycle Proteins Multiprotein Complexes Quinazolines Tic10 Adolescent Fluorouracil Fancc Cultured Tumor Cells Therapeutic targets Bispecific Antibodies Thiazoles Rituximab Cytarabine United States Neutropenia Insulin-Like Growth Factor II Neoplasm Transplantation Interferon-gamma Androgen Antagonists Antineoplastic Combined Chemotherapy Protocols Capillary Permeability Syndrome Monoclonal Antibodies-Murine-Derived
Last updated on Friday, January 03, 2020